Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02378038 · ClinicalTrials.gov registry record · Phase 2
PNT2258 for Treatment of Patients With Richter's Transformation (Brighton)
A Phase 2 study, sponsored by Sierra Oncology LLC - a GSK company.
- Terminated
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
NCT02378038: Clinical Trial Phase 2 study, sponsored by Sierra Oncology LLC - a GSK company.
NCT02378038 is a Phase 2 study that was terminated before completion, run by Sierra Oncology LLC - a GSK company. The registered enrollment target is 5 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02378038, a Phase 2 study, was terminated before completion, sponsored by Sierra Oncology LLC - a GSK company.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
Study Summary
This study is sponsored by Sierra Oncology, Inc. formerly ProNAi Therapeutics, Inc. It is a multi-center, single-arm, 2-stage, open-label phase II investigation of PNT2258 to characterize anti-tumor activity and collect safety data on patients with Richter's Transformation.
Primary Outcome
Proportion of subjects with complete response (CR/CMR) or partial response (PR/PMR)
Interventions
- DRUG PNT2258
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2015-08 |
| Est. Completion | 2016-06 |
| Phase | Phase 2 |
Why NCT02378038 stopped before completion
NCT02378038 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 1 intervention - of which PNT2258 is the first listed.
NCT02378038 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02378038 about?
NCT02378038 is a clinical study titled "PNT2258 for Treatment of Patients With Richter's Transformation (Brighton)". This study is sponsored by Sierra Oncology, Inc. formerly ProNAi Therapeutics, Inc. It is a multi-center, single-arm, 2-stage, open-label phase II investigation of PNT2258 to characterize anti-tumor activity and collect safety data on patients with Richter's Transformation.
What is the current status of trial NCT02378038?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2015-08. Estimated completion is 2016-06.
What interventions are being tested in trial NCT02378038?
The interventions under investigation include: PNT2258 (DRUG).
Who is sponsoring clinical trial NCT02378038?
This trial is sponsored by Sierra Oncology LLC - a GSK company, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02378038's enrollment target sits among peer trials
5 2000th of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia